第24届亚太地区肝脏研究协会年会（APASL 2014）于2014年3月12～15日在澳大利亚布里斯班召开。会上日本北九州的岩本正三博士介绍了血管造影术下亚肝段切除术在肝细胞癌治疗中的应用。

在血管造影术下亚肝段切除术中，使用CT扫描联合血管造影术以确定肿瘤供血动脉，将碘油和抗肿瘤药物直接注入到肿瘤所在部位，与此同时供血动脉则可以被海绵凝胶阻断。接下来，回流静脉被抗肿瘤药物所引起的肿瘤坏死病灶所堵塞从而达到靶向治疗的目的。

从1998年起，这种治疗方法一直被日本北九州的岩本门诊部作为治疗肝细胞癌的一线方法。岩本正三博士带来的这项试验进一步明确了其有效性。

研究详情

总共有227名患者接受了该手术。岩本正三博士总结到：“227名肝癌患者的五年生存率分别为一期65.9%，二期54.9%，三期20.6%，4期15.7%。十年生存率为一期36.4%，二期17.9%。”

然而，如果排除其他所有死因，这些患者的5年生存率将提高至一期75.3%，二期59.3%，三期23.6%，4期18.8%。十年生存率将提高至一期43.0%，二期19.4%。这些数据在第一次接受该治疗的患者中甚至更高。
 

这种技术，由已故的奥田雄邦教授首创，最初在2003被倡导使用，从此被大家所重视成为治疗肝细胞癌的一种可行的一线方法。
 

原文阅读》》》Angiographic Subsegmentectomy in HCC
 

Angiographic Subsegmentectomy (AS) is a procedure wherein computed tomographyis combined with angiography to identify the arteries that feed the tumour directly. Iodinised oil (lipiodol) and anti-cancer drugs are fed directly to the site of the cancer, while the feeding artery is occluded by gelatin sponge particles. The vein, consequently, is occluded by the necrotic actions of the cancer drugs and allows for targeted treatment of the cancer.
 

This therapy has been the first line for HCC treatment in the Iwamoto Clinic (Kitakyushu, Japan) since 1998. This trial represents a further validation of its efficacy. 
 

The operation was performed on 227 patients.“Five–year survival rates of these 227 patients,”writes Dr. Shozo Iwamoto,“were 65.9% in stage I, 54.9% in stage II, 20.6% in stage III, 15.7% in stage IV; ten-year survival rates were 36.4% in stage I, 17.9% in stage II.”
 

However, if all other causes of death were excluded, these rates jump to 75.3% in stage I, 59.3% in stage II, 23.6% in stageIII, and 18.8% in stage IV. 10-year survival rates were 43.0% in stage I, 19.4% in stage II. The rates are even higher in those whom were first treated with AS. 
 

This technique, pioneered by the late Professor Kunio Okuda, was originally suggested in 2003 and has since gained traction as a viable first-line therapy for HCC patients.
 

来源：APASL 2014 daily news